|
US6402215B1
(en)
*
|
1996-05-21 |
2002-06-11 |
American Moto Products, Inc. |
Vehicle cargo bed extender
|
|
CA2744997A1
(en)
|
2003-09-26 |
2005-04-07 |
Exelixis, Inc. |
C-met modulators and method of use
|
|
WO2006014325A2
(en)
|
2004-07-02 |
2006-02-09 |
Exelixis, Inc. |
C-met modulators and method of use
|
|
JP2008537748A
(ja)
|
2005-04-06 |
2008-09-25 |
エクセリクシス、インコーポレイテッド |
ｃ−Ｍｅｔモジュレーター及び使用方法
|
|
ES2703723T3
(es)
|
2006-12-14 |
2019-03-12 |
Exelixis Inc |
Métodos para usar inhibidores de MEK
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
AR075084A1
(es)
|
2008-09-26 |
2011-03-09 |
Smithkline Beecham Corp |
Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
|
|
CA2743416A1
(en)
|
2008-11-13 |
2010-05-20 |
Exelixis Inc. |
Methods of preparing quinoline derivatives
|
|
EP2367795A1
(en)
|
2008-12-04 |
2011-09-28 |
Exelixis, Inc. |
Methods of preparing quinoline derivatives
|
|
EA038195B1
(ru)
|
2009-01-16 |
2021-07-22 |
Экселиксис, Инк. |
Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
|
|
EP2454238A1
(en)
|
2009-07-17 |
2012-05-23 |
Exelixis, Inc. |
Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
JP5714030B2
(ja)
*
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
|
|
EP2545038A1
(en)
|
2010-03-12 |
2013-01-16 |
Exelixis, Inc. |
Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
WO2012009722A1
(en)
|
2010-07-16 |
2012-01-19 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
US20140186407A9
(en)
|
2010-07-16 |
2014-07-03 |
Exelixis Inc. |
C-Met Modulator Pharmaceutical Compositions
|
|
DK2621481T4
(da)
|
2010-09-27 |
2023-01-09 |
Exelixis Inc |
Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
|
|
CN103391773A
(zh)
|
2010-09-27 |
2013-11-13 |
埃克塞里艾克西斯公司 |
用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
|
|
JP2013540759A
(ja)
|
2010-09-27 |
2013-11-07 |
エクセリクシス， インク． |
去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
|
|
WO2012064967A2
(en)
*
|
2010-11-10 |
2012-05-18 |
Cedars-Sinai Medical Center |
Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
|
|
JP2013543011A
(ja)
|
2010-11-22 |
2013-11-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド |
癌の治療法
|
|
TWI640509B
(zh)
|
2011-02-10 |
2018-11-11 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
TWI610918B
(zh)
|
2011-05-02 |
2018-01-11 |
艾克塞里克斯公司 |
治療癌症及骨癌疼痛之方法
|
|
TW201306842A
(zh)
|
2011-06-15 |
2013-02-16 |
Exelixis Inc |
使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
EP2768796B1
(en)
|
2011-10-20 |
2019-11-20 |
Exelixis, Inc. |
Process for preparing quinoline derivatives
|
|
EP2776033A1
(en)
|
2011-11-08 |
2014-09-17 |
Exelixis, Inc. |
Dual inhibitor of met and vegf for treating cancer
|
|
WO2013119693A1
(en)
*
|
2012-02-06 |
2013-08-15 |
The Regents Of The University Of California |
Emp2 regulates angiogenesis in cancer cells through induction of vegf
|
|
CN103304552B
(zh)
*
|
2012-03-09 |
2016-12-28 |
广东东阳光药业有限公司 |
取代的吡啶化合物及其使用方法和用途
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
EP2892532B1
(en)
|
2012-09-07 |
2019-02-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
|
US20140221372A1
(en)
|
2013-02-06 |
2014-08-07 |
GlaxoSmithKline Intellectual Property (NO 2.) Limited |
Method of administration and treatment
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
KR20150138268A
(ko)
|
2013-04-04 |
2015-12-09 |
엑셀리시스, 인코포레이티드 |
암을 치료하기 위한 약물 병용요법
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
AU2015218236B2
(en)
|
2014-02-14 |
2019-06-13 |
Exelixis, Inc. |
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
|
|
US10159666B2
(en)
|
2014-03-17 |
2018-12-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
EP3906921A1
(en)
|
2014-04-25 |
2021-11-10 |
Exelixis, Inc. |
Method of treating lung adenocarcinoma
|
|
CN106715397B
(zh)
|
2014-07-31 |
2021-07-23 |
埃克塞里艾克西斯公司 |
制备氟-18标记的卡博替尼及其类似物的方法
|
|
BR112017002318A2
(pt)
|
2014-08-05 |
2018-07-17 |
Exelixis, Inc. |
combinações de fármacos para tratar mieloma múltiplo.
|
|
US20170224670A1
(en)
|
2014-10-14 |
2017-08-10 |
Exelixis, Inc. |
Drug Combination to Treat Melanoma
|